Adherium (ASX:ADR) announced a data-based initiative with Summatix to allow clinicians to improve care of patients with asthma and chronic obstructive pulmonary disease across the world.
New Zealand-based Adherium and Australia-based Summatix plan to build upon an existing relationship, as the former will gain access to Summatix’s platform to release data from its Hailie sensors for clinical and other relevant use. That platform allows for connected external and implanted medical device integration and shares the resulting data with patients, clinicians, payers and the device manufacturer.
Get the full story at our sister site, Drug Delivery Business News.